Vivos Therapeutics announced it will acquire an 11% equity stake in SOD Sciences and a 50% co-ownership in SOD's proprietary pseudohypoxia early-warning test by issuing $12 million in preferred stock. This deal opens potential collaborations with Cleveland Clinic and American Health Associates, aiming to enhance Vivos' diagnostic and treatment offerings for sleep apnea and related conditions. The transaction is expected to increase Vivos' stockholders' equity and support Nasdaq compliance efforts, with plans to expand operations and target profitability in early 2027. The partnership could lead to new revenue streams from the test and joint marketing initiatives, pending regulatory and clinical validations.
Vivos Therapeutics' recent deal involves issuing $12 million in preferred stock to acquire stakes in SOD Sciences and its pseudohypoxia test. For readers following the US health sector, here is Pluang's market snapshot as of Oct 15, 2026 19:31 WIB: out of 150 priced health stocks, 95 rose and 46 fell. Notable movers include AstraZeneca plc (AZN) at USD 167.07 with a 3.11% gain and Cassava Sciences Inc (FLNA) at USD 0.71, down 3.23%, with Pluang order activity showing a slight buy preference for FLNA and AZN.
TiDB, powered by PingCAP, announced new cloud platform capabilities to support enterprise and AI applications on a unified data foundation. Key updates include the upcoming general availability of TiDB Cloud Premium, public previews of Bring Your Own...
The Saudi Arabia Non-Invasive Prenatal Testing (NIPT) market is projected to grow from $52.5 million in 2025 to $162.16 million by 2034, at a CAGR of 13.35%. Growth is fueled by rising maternal age, advances in molecular diagnostics, and increased he...
ONEOK completed a $4.425 billion acquisition of Brazos Midstream's natural gas assets, doubling its processing capacity in the Permian Midland Basin to about 2.3 billion cubic feet per day. The deal secures 600,000 acres under long-term contracts, st...
Charles Schwab reported Q3 earnings per share of $1.69, beating estimates despite slightly missing revenue forecasts with $7.17 billion. The quarter marked a 17% revenue increase year-over-year and a 23% rise in net income to $2.91 billion, driven by...
Alcoa will release its Q3 2026 earnings on October 15, with analysts divided on earnings per share and revenue forecasts due to factors like rising aluminum sales, inventory changes, and higher input costs. The company expects a 54.9% jump in aluminu...
